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OBJECTIVES: Occurrence of weight gain during antipsychotic
therapy may not only lead to increased metabolic or cardiovas-
cular risks but may also inﬂuence treatment effectiveness,
reﬂected by adherence to antipsychotic therapy. Aim of this
analysis is to link weight gain during treatment with olanzapine
and aripiprazole in clinical trials to medication non-adherence
and, in consequence, to relapse and cost of relapse from a Finnish
perspective, based on comparable efﬁcacy in treating schizo-
phrenia. METHODS: In a web-based interview, 104 Finnish psy-
chiatrists described the impact of antipsychotic treatment-related
weight gain on adherence and estimated the percentage of their
patients with schizophrenia becoming non-adherent, when expe-
riencing >7% weight gain during six months of antipsychotic
treatment. The result was linked to the primary efﬁcacy outcome
measure, percentage of patients showing signiﬁcant (>7%)
weight gain, in a 26-week random clinical trial of aripiprazole
vs. olanzapine. Drug non-adherence-related relapse data and
costs of treating relapse were derived from published sources.
Cost analysis was based on Finnish payer’s perspective.
RESULTS: After 26 weeks, 33% in the olanzapine group showed
>7% weight gain, compared to 13% with aripiprazole. Finnish
psychiatrists estimated 18% of their patients becoming non-com-
pliant when experiencing >7% weight gain within 6 months of
antipsychotic therapy. The percentage of medication non-
compliant patients who experienced a relapse is 37%. Results
show a relative risk reduction estimate for relapse due to weight
gain related non-adherence of 64% with aripiprazole versus
olanzapine. When treating 1000 patients with aripiprazole
instead of olanzapine over 6 months, 14 relapses due to weight
gain related non-adherence could be avoided, with estimated cost
savings of 180,950€ due to avoided acute relapse treatment in
Finnish hospitals. CONCLUSIONS: Results highlight improved
effectiveness with medical and economic beneﬁt of aripiprazole
versus olanzapine, reﬂected by potentially reduced relapse rates
due to weight gain induced non-adherence.
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OBJECTIVES: To describe real life disease characteristics, side
effects and socioeconomic situations for schizophrenia inpatients
and outpatients treated with olanzapine or haloperidol over 12
months. METHODS: GEO is a German 2-year prospective nat-
uralistic observational study. Quarterly observations were made
for 289 patients included in the study under olanzapine treat-
ment and 187 patients included under haloperidol treatment.
RESULTS: During the 12 months study period, olanzapine and
haloperidol treatment was stable (olanzapine: 96% of follow up
days with study medication coverage vs. haloperidol: 94%; med-
ication or dosage changes 56% vs. 38%). General, negative and
cognitive symptoms ranged from “moderate” to “clearly ill”
(average CGI summary scores 3–4). Positive and depressive
symptoms ranged from “mild” to “moderate” (CGI 2–3).
During the course of the study, disease severity improved for all
symptoms (p < 0.05; not signiﬁcant for haloperidol positive and
depressive score) with slightly better improvement in olanzapine
patients. Throughout the study period, signiﬁcantly fewer olan-
zapine patients had extrapyramidal side effects. Average
extrapyramidal, parkinsonism, retardation and akathisia side
effects were milder in olanzapine patients. Other side effects were
reported more frequently for olanzapine (<28% vs. <8%). Con-
comitant schizophrenia-related medication was prescribed sig-
niﬁcantly less frequently for olanzapine patients (48% vs. 64%).
Compared to haloperidol patients, more patients under olanza-
pine were able to care for themselves (86% vs. 79%), lived at
home without care (58% vs. 39%), were employed (34% vs.
17%), and fewer were in early retirement (29% vs. 49%). CON-
CLUSIONS: In Germany, real life schizophrenia patients under
olanzapine treatment showed a higher degree of integration into
social and occupational environment. For olanzapine patients,
all schizophrenia symptoms signiﬁcantly improved over time.
Additionally, olanzapine patients exhibited less extrapyramidal,
parkinsonism, retardation and akathisia side-effects than
patients treated with haloperidol.
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OBJECTIVES: To examine time to re-hospitalisation and re-
hospitalisation rates of patients who had been discharged from
psychiatric hospitals after starting treatment with either risperi-
done or olanzapine. METHODS: A multi-centre retrospective
cohort study was carried out in 9 centres in 3 countries. Re-
hospitalisation status was monitored in 393 schizophrenia
patients previously discharged on one of the two study drugs.
Data were collected using a pre-deﬁned; standardised data col-
lection template. The proportion of re-hospitalised patients were
compared between risperidone and olanzapine using the
Cochran-Mantel-Haenszel test stratiﬁed by centre. Time to re-
admission was assessed and compared between the two groups
of patients using Kaplan-Meier curves, log-rank test and Cox
proportional hazard models. RESULTS: Median follow up was
1282 days in the risperidone group and 1207 days in the olan-
zapine group, ranging from 93 to 2985 days across both groups.
The proportion of re-hospitalised patients was lower for patients
discharged on risperidone (59%) than for patients discharged on
olanzapine (66%) (p = 0.089). Reason for re-hospitalisation was
similar in both groups with 65% and 68% of all re-admissions
in the risperidone and olanzapine group respectively due to
relapse of schizophrenia, with 42% (192 cases) of all re-hospi-
talisations linked to non-compliance. The time to ﬁrst re-admis-
sion was longer in the risperidone group (KM median estimate:
925 days; 95%CI: 660–1249 days) than in the olanzapine group
